Novo Nordisk

With an eye on rivals, Novo Nordisk launches diabetes drug Ozempic in India

With Mounjaro gaining ground, launch comes just three months before Novo loses patent for semaglutide

Novo Nordisk challenges HC order permitting Dr Reddy's semaglutide exports

Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

Delhi HC refuses to halt order allowing Dr Reddy's to export Semaglutide

The Delhi High Court refused to stop an earlier order that lets Dr Reddy's make Semaglutide in India only for export, saying Novo Nordisk's patent challenge needs a full hearing before any decision

Delhi HC allows Sun Pharma to export semaglutide, restricts sale in India

The Delhi High Court has allowed Sun Pharma to manufacture and export semaglutide-based drugs to countries where Novo Nordisk holds no patent, but barred sales in India until March 2026

Delhi HC allows Sun Pharma to manufacture, export its weight loss drug

The approval marks a major win for Sun Pharma in its patent dispute with Danish drugmaker Novo Nordisk, the company that manufactures weight loss drug Ozempic

Novo Nordisk moves HC to stop Sun Pharma's weight-loss drug launch

The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for Type 2 diabetes and weight management

Price cuts drove market gains in November for Novo Nordisk's Wegovy

Novo Nordisk cut Wegovy prices in mid-November, driving a 70% consumption jump and higher market share. Pharmarack data show Lilly's Mounjaro still dominates sales

Healthify seeks more weight-loss drug partnerships after Novo Nordisk deal

The deal marks Healthify's first such partnership with a drugmaker, and it hopes similar agreements will boost its paid subscriber base

Novo sticks to oral semaglutide amid rising demand for injectables

Novo Nordisk will strengthen its oral semaglutide portfolio led by Rybelsus while cutting Wegovy injection prices by up to 37% to improve accessibility and expand its market in India

Novo Nordisk cuts weight-loss drug Wegovy prices by up to 37% in India

Move comes in a bid to gain more space in India's anti-obesity market dominated by Mounjaro

Novo Nordisk, Emcure Pharmaceuticals tie up to expand Wegovy's girth

2.4 mg injectable Poviztra to mark next phase of weight-loss rollout

Novo Nordisk, Emcure Pharma to launch weight-loss drug under new brand

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk's reach is limited

Pfizer signs deal with Metsea after bidding war with Novo Nordisk

The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity

India to get Novo Nordisk's Ozempic soon as demand for obesity drugs surges

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

Ozempic maker Novo Nordisk to cut 9,000 job to save $1.3 billion annually

Novo Nordisk will cut 11.5 per cent of its workforce to save costs and streamline operations as competition rises and sales of Wegovy and Ozempic slow, especially in the US market

Will this court fight make the world's hottest weight-loss drug cheaper?

Indian pharma takes Novo Nordisk to court over patents that keep Wegovy and Ozempic out of reach - could this slash prices for millions of patients?

Denmark aims to build world's most powerful quantum computer, Magne

Microsoft, which has its largest quantum lab in Denmark, will provide software and Atom Computing will build the quantum computer

IIM Ahmedabad, Novo Nordisk India partner to boost obesity care ecosystem

The Indian Institute of Management Ahmedabad on Wednesday said it has signed an agreement with Novo Nordisk India to strengthen the obesity care ecosystem in the country for five years till 2030. The memorandum of understanding, inked on Tuesday, aims to strengthen the healthcare ecosystem in India through a multi-dimensional approach focused on non-communicable diseases (NCDs), especially obesity, the Indian Institute of Management Ahmedabad (IIMA) said in a statement. "This collaboration with Novo Nordisk India brings together healthcare and public policy, two domains where data and research can enable lasting change. At IIMA, we aim to apply our academic rigour to generate actionable insights for policymakers, healthcare professionals, and communities tackling non-communicable diseases like obesity," IIM Ahmedabad Director Professor Bharat Bhasker said. As a part of this collaboration, Novo Nordisk India (NNIPL) and IIMA will co-develop and implement impactful programmes under ..

Demand for obesity drugs soars in India as Lilly, Novo jostle for mkt share

Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst three globally for high obesity rates

Obesity drug race begins: Wegovy launches in India | Novo Nordisk | Weight loss drug | Pharma sector

Danish pharma giant Novo Nordisk has brought its weight-loss drug Wegovy to India. This follows US company Eli Lilly’s launch of Mounjaro just 3 months ago.